Legal & General Group
BCYC

Legal & General Group’s Bicycle Therapeutics BCYC Stock Holding History

Legal & General Group’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,054
Closed -$39.2K – 3406
2026
Q1 		$39.2K Hold
9,054
– – ﹤0.01% 2737
2025
Q4 		$64.1K Sell
9,054
-188,863
-95% -$1.39M ﹤0.01% 2680
2025
Q3 		$1.53M Buy
197,917
+23,007
+13% +$174K ﹤0.01% 2087
2025
Q2 		$1.21M Buy
174,910
+39,252
+29% +$313K ﹤0.01% 2175
2025
Q1 		$1.17M Sell
135,658
-3,417
-2% -$40.3K ﹤0.01% 2131
2024
Q4 		$1.95M Sell
139,075
-99,741
-42% -$2.14M ﹤0.01% 1987
2024
Q3 		$5.4M Sell
238,816
-8,998
-4% -$208K ﹤0.01% 1540
2024
Q2 		$5.02M Buy
247,814
+114,746
+86% +$2.59M ﹤0.01% 1523
2024
Q1 		$3.31M Buy
133,068
+263
+0.2% +$5.59K ﹤0.01% 1714
2023
Q4 		$2.4M Buy
132,805
+40,342
+44% +$667K ﹤0.01% 1861
2023
Q3 		$1.86M Buy
92,463
+12,207
+15% +$279K ﹤0.01% 1931
2023
Q2 		$2.05M Buy
80,256
+67,097
+510% +$1.56M ﹤0.01% 1923
2023
Q1 		$280K Buy
13,159
+2,626
+25% +$65.9K ﹤0.01% 2474
2022
Q4 		$312K Buy
10,533
+1,400
+15% +$37.6K ﹤0.01% 2454
2022
Q3 		$212K Hold
9,133
– – ﹤0.01% 2603
2022
Q2 		$154K Sell
9,133
-2,133
-19% -$45K ﹤0.01% 2727
2022
Q1 		$495K Buy
11,266
+1,206
+12% +$56.3K ﹤0.01% 2399
2021
Q4 		$612K Sell
10,060
-148
-1% -$8.17K ﹤0.01% 2355
2021
Q3 		$423K Buy
10,208
+2,177
+27% +$76.1K ﹤0.01% 2469
2021
Q2 		$244K Buy
+8,031
New +$243K ﹤0.01% 2481

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Legal & General Group's BCYC Position: Q2 2026 in Review

Legal & General Group sold out of Bicycle Therapeutics (BCYC) in Q2 2026, closing a stake of 9,054 shares — an estimated $39.2K sold.

Legal & General Group first reported a position in BCYC in Q2 2021 and held it in 20 quarters. The position peaked at $5.4M in Q3 2024. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Legal & General Group reported no remaining Bicycle Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Legal & General Group sold 9,054 Bicycle Therapeutics shares in Q2 2026, an estimated $39.2K.
  • Legal & General Group first reported a position in Bicycle Therapeutics in Q2 2021 and held it in 20 quarters.
  • Legal & General Group's Bicycle Therapeutics position peaked at $5.4M in Q3 2024.
  • 103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.